Research programme: microRNA modulators - Mirrx Therapeutics

Drug Profile

Research programme: microRNA modulators - Mirrx Therapeutics

Alternative Names: Blockmirs for hepatitis C - Mirrx Therapeutics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stealth Biotech
  • Developer Mirrx Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Gene expression modulators; MicroRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Denmark
  • 16 Feb 2010 Preclinical trials in Hepatitis C in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top